21/06/2026
What's your spot diagnosis?
Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor suppressor gene VHL, located on the short arm of chromosome 3. While the majority of the affected individuals have a positive family history, up to 20% of cases arise from de novo mutations. .
VHL syndrome is characterized by the presence of benign and malignant tumors affecting the central nervous system, kidneys, adrenals, pancreas, and reproductive organs.
Common manifestations include hemangioblastomas of the brain, spinal cord, and retina; pheochromocytoma and paraganglioma; renal cell carcinoma; pancreatic cysts and neuroendocrine tumors; and endolymphatic sac tumors.
Diagnosis of VHL is prompted by clinical suspicion and confirmed by molecular testing. Management of VHL patients is complex and multidisciplinary. Routine genetic testing and surveillance using various diagnostic techniques are used to help monitor disease progression and implement treatment options.
Despite recent advances in clinical diagnosis and management, life expectancy for VHL patients remains low at 40–52 years.
Retinal hemangioblastomas arise frequently in VHL patients. They are seen in as many as 60% of patients. Although not the most common tumor in VHL, they are often the first manifestation. The median age of onset is 21, which is the lowest among the other clinical features.
These retinal lesions are symptomatic at presentation. All patients who present with one retinal hemangioblastoma will likely develop bilateral lesions by age 56.
Complications of retinal hemangioblastomas include blindness or severe visual deficits in 5–8% of VHL patients. The disease may occur at the periphery or optic nerve. Both can lead to symptoms as a result of the accumulation of subretinal fluid and development of hard exudates in the macula.
Worse visual outcomes are associated with early age of onset of ocular disease, bilateral involvement, and missense mutations in VHL.
Subscribe for exclusive ophthalmology content, case presentation/publications, detailed case analyses, fundus interpretations, and eye health updates.
Your support helps us continue sharing high-quality educational content for eye care professionals and enthusiasts.